Evommune, INC. (EVMN) — S-1/A Filings
All S-1/A filings from Evommune, INC.. Browse 1 S-1/A reports with AI-powered summaries and risk analysis.
S-1/A Filings (1)
-
Evommune IPO Targets $15-$17/Share Amid Promising Phase 2 Data
— Oct 17, 2025 Risk: high
Evommune, Inc. (EVMN) is a clinical-stage biotechnology company focused on chronic inflammatory diseases, with two product candidates, EVO756 and EVO301, in Pha
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX